Li-Fraumeni syndrome, familial occurance of cancer, cancer predisposition syndromes
Conditions
Interventions
Group 1: Natural History Study.
Data and biospecimen of patients with cancer predisposition syndromes are collected once a year.
- Evaluation of the feasibility and benefit of cancer surveillance prog
Sponsors
Medizinische Hochschule HannoverZentrum für Kinderheilkunde und JugendmedizinKlinik für Pädiatrische Hämatologie und Onkologie
Eligibility
Sex/Gender
All
Age
No minimum to 120 Years
Inclusion criteria
Inclusion criteria: Proven cancer predisposition syndrome, high-level suspicion of a cancer predisposition syndrome
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of cancer Development of non-malignant complications Physical anomalies Death | — |
Secondary
| Measure | Time frame |
|---|---|
| What is the benefit of the early detection recommended by experts? Are there genotype-phenotype correlations? How high are the cancer risks in different age groups? What is the prognosis of cancer in patients with a genetic predisposition to cancer? What are the particular side effects of the therapy? How can the therapy of people with a predisposition to cancer be improved? What are the biological processes that lead to the development of cancer? | — |
Countries
Austria, Croatia, Germany, Greece, Switzerland
Contacts
Public ContactChristian Kratz
Medizinische Hochschule HannoverZentrum für Kinderheilkunde und JugendmedizinKlinik für Pädiatrische Hämatologie und Onkologie
Outcome results
None listed